Mock 2005.

Study characteristics
Methods	Study design: RCT Number randomized: 119; 60 to the exercise group and 59 to the control group Study start and stop dates: recruitment between 1998 and 2001 Length of intervention: for the duration of treatment, 6 weeks if radiation therapy or 3 to 6 months if chemotherapy Length of follow‐up: to end of the intervention
Participants	Type cancer: breast cancer Stage, % exercise group: Stage 0, 20%; Stage I, 45%; Stage II, 35%; Stage IIIa, 0% control group: Stage 0, 27.2%; Stage I, 40.7%; Stage II, 25.4%; Stage IIIa, 6.7% Time since cancer diagnosis: not reported Time in active treatment: initiating adjuvant therapy Inclusion criteria: 18 to 70 years old Eligibility criteria related to interest or ability, or both, to exercise: concurrent major health problems that could affect participation in an exercise program, including obesity (BMI > 35 kg/m2), cardiovascular disease, acute or chronic respiratory disease, cognitive dysfunction engaged in active exercise (> 45 minutes per week) Exclusion criteria: no additional exclusions Gender: female Current age, mean (SD) years: exercise group: 51.3 (8.9) years control group: 51.6 (9.7) years Age at cancer diagnosis: not reported Ethnicity/race, % Caucasian: exercise group: 85.0% control group: 79.3% Education level, years of education, mean (SD) years: exercise group: 15.1 (2.8) years control group: 14.9 (2.7) years SES: not reported Employment status: 73% employed Comorbidities: not reported Past exercise history: not reported On hormone therapy: not reported Adjuvant treatment: radiation therapy, 58%; chemotherapy, 42%
Interventions	60 participants assigned to the exercise intervention, including: walking briskly for 15 minutes and increasing to 30 minutes as training progressed Type exercise (aerobic/anaerobic): aerobic Intensity of the experimental exercise intervention: target HR range of ~ 50% to 70% of maximum HR Frequency: 5 or 6 times per week Duration of individual sessions: 45 minutes Duration of exercise program: 6 weeks for radiation or 3 to 6 months for chemotherapy Total number of exercise sessions: varied Format: individual Facility: home Not professionally led Adherence: defined as engaging in ≥ 60 minutes of aerobic activity for at least 67% of the duration of the trial: 39/54 (72%) adhered 59 participants assigned to control group, including: usual care, with contact from the research team every 2 weeks for attention control Contamination of control group: defined as exceeding 45 minutes of aerobic activity weekly for 67% of the duration of the trial: 33/54 (61%) were not contaminated; 39% were contaminated
Outcomes	Primary outcome: fatigue, assessed using the PFS Other outcomes included physical function, assessed using 12‐MWT SF‐36 Physical Function Scale Physical Activity Questionnaire Outcomes were measured at baseline and end of the intervention: exercise group: n = 54 at baseline, n = 54 at end of the intervention control group: n = 54 at baseline n = 54 at end of the intervention Subgroup analysis: high walkers (>60 minutes per week in ≥ 3 sessions) versus low walkers (< 60 minutes per week or not at all) Adverse events: not reported
Notes	Country: US Funding: Fatigue Initiative in Research and Education multi‐institutional award from the Oncology Nursing Society Foundation
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer generated
Allocation concealment (selection bias)	Low risk	Number sealed opaque envelopes
Blinding of participants and personnel (performance bias) All outcomes	High risk	Owing to the nature of the intervention, it was not possible to conceal allocation to the intervention from the participants
Blinding of outcome assessment (detection bias) All outcomes	High risk	Study personnel and outcome assessors were not masked or blinded to the study interventions
Incomplete outcome data (attrition bias) All outcomes	High risk	No ITT analyses were performed and 6 participants withdrew from the exercise group and 5 form the control group
Selective reporting (reporting bias)	Low risk	There is no evidence of selective reporting of outcomes
Other bias	Low risk	The trial appears to be free of other problems that could put it at a high risk of bias